½ÃÀ庸°í¼­
»óǰÄÚµå
1611407

¼¼°èÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : À¯Çü, ¹æ»ç¼º µ¿À§ ¿ø¼ÒÀÇ À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Single Photon Emission Computed Tomography Market by Type (Hybrid SPECT Systems, Standalone SPECT Systems), Type of Radioisotopes (Ga-67, I-123, Ra-223), Application, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 187 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀº 2023³â 20¾ï9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â 21¾ï9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.04%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 27¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(SPECT)Àº °¨¸¶¼±À» »ç¿ëÇÏ¿© ½ÅüÀÇ ±â´ÉÀû °úÁ¤ÀÇ »ó¼¼ÇÑ 3 Â÷¿ø ¿µ»óÀ» Á¦°øÇÏ´Â ÇÙ ¿µ»ó ±â¼úÀ̸ç, ÀϹÝÀûÀ¸·Î ½ÉÀå º´ÇÐ, ½Å°æÇÐ, Á¾¾çÇÐÀ¸·Î Áø´Ü Ä¡·á °èȹ¿¡ »ç¿ëµË´Ï´Ù. PECTÀÇ Çʿ伺Àº ½ÅÁø ´ë»çÀÇ º¯È­¸¦ °­Á¶ÇÔÀ¸·Î½á Áúº´À» Á¤È®Çϰí Á¶±â¿¡ ¹ß°ßÇÏ°íº¸´Ù È¿°úÀûÀÎ °³ÀÔÀ» °¡´ÉÇϰÔÇÏ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. Áß °ü»ó µ¿¸Æ Áúȯ°ú Á¾¾ç ¹ß°ß µî, Áúº´¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®À» Á¦°øÇÏ´Â SPECTÀÇ ´É·ÂÀº ¸Å¿ì ±ÍÁßÇÑ °ÍÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀº À̹ÌÁö ¾ç½ÄÀÇ °³¼±À̳ª SPECT/CT¿Í °°Àº ÇÏÀ̺긮µå À̹ÌÁö ±â¼ú µîÀÇ ±â¼ú Áøº¸ÀÇ ¿µÇâÀ» ¹Þ¾Æ Å©°Ô ¼ºÀåÇϰí Áø´Ü ´É·ÂÀ» ³ôÀ̰í ÀÓ»ó ÀÀ¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. °³¼±ÇÔÀ¸·Î½á Áø´Ü ½Ç¼ö¸¦ ÁÙÀÔ´Ï´Ù. ÀýÂ÷ÀÇ È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀåÀº °í°¡ÀÇ Àåºñ ºñ¿ë, Á¦ÇÑµÈ »óȯ Á¤Ã¥, ¿î¿µ ¹× ºÐ¼®¿¡ ÇÊ¿äÇÑ Àü¹® ±â¼ú°ú °°Àº °úÁ¦¿¡ Á÷¸éÇÕ´Ï´Ù. ½ÅÈï ±¹°¡ÀÇ Ã¤¿ë·ü Áö¿¬ÀÌ Å®´Ï´Ù. ÀÌ·¯ÇÑ Á¦¾àÀÌ µÉ °¡´É¼ºµµ ÀÖ½À´Ï´Ù.À̸¦ ±Øº¹Çϱâ À§Çؼ­´Â ºñ¿ë È¿À²ÀûÀÎ ¼ÒÇü ½Ã½ºÅÛÀÇ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ È®´ë¿Í AI Çõ½ÅÀ» À§ÇÑ ÇÏÀÌÅ×Å© ±â¾÷°úÀÇ Çù¾÷ÀÌ ¸Å¿ì Áß¿äÇÒ °¡´É¼º °¡ ÀÖ½À´Ï´Ù. ·Î´Â ¸ÂÃãÇü ¼Ö·ç¼ÇÀ»À§ÇÑ ÀÇ·á ½Ã¼³°úÀÇ Á¦ÈÞ¿Í ¹Ì°³Ã´ ½ÃÀå ÁøÃâ¿¡ ÁÖ·ÂÇÏ´Â °ÍÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¾ß ¾×¼¼½Ãºô¸® Ƽ¿¡ ´ëóÇÒ °¡´É¼ºÀÌ ÀÖ¾î, ÀÌ °³¹ß µµ»óÀÇ ºÐ¾ß¿¡ À־ÀÇ À¯¸ÁÇÑ ¿¬±¸ ºÐ¾ß¶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù. °³Ã´ÀÇ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 20¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 21¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 27¾ï 7,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 4.04%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. °áÁ¤ÀÇ Á¤±³È­¿Í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñ ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¼Òºñ ÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¿©·¯ À¯ÇüÀÇ ¾ÏÀÇ À¯º´·üÀÇ »ó½Â°ú °íµµÀÇ À̹Ì¡ ±â¼úÀÇ Çʿ伺
    • ¹æ»ç¼º ÀǾàǰ¿¡¼­ SPECT ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¹æ»ç¼º µ¿À§ ¿ø¼ÒÀÇ ¹Ý°¨±âÀÇ ÂªÀ½
  • ½ÃÀå ±âȸ
    • ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ¹ýÀÇ Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ÆÆ¼ÆÑÆ®¿Í °¨¼èÀÇ ¿µÇâÀ» ¹Þ±â ½±´Ù

Porter's Five Forces : ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½ÃÀû ȯ°æ ¿äÀÎÀº ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î¸¦ ±×¸®±â

´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇöÀç Áõ´ë¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀÇ ÀÌȯÀ² Áõ°¡¿Í °í±Þ ¿µ»ó Áø´Ü ±â¼úÀÇ Çʿ伺
      • ¹æ»ç¼ºÀǾàǰ¿¡ À־ÀÇ SPECT ºÐ¼® ¼ö¿ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ¹æ»ç¼º µ¿À§ ¿ø¼ÒÀÇ ¹Ý°¨±â°¡ ªÀº
    • ±âȸ
      • ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µÀÇ Áøº¸
    • °úÁ¦
      • ¾ÆÆ¼ÆÑÆ®³ª °¨¼è°¡ ¹ß»ýÇϱ⠽¬¿î
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : À¯Çüº°

  • ÇÏÀ̺긮µå SPECT ½Ã½ºÅÛ
  • µ¶¸³Çü SPECT ½Ã½ºÅÛ

Á¦7Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : ¹æ»ç¼º µ¿À§ ¿ø¼ÒÀ¯Çüº°

  • Ga-67
  • I-123
  • Ra-223
  • TC-99M

Á¦8Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : ¿ëµµº°

  • ½ÉÀ庴ÇÐ
  • ½Å°æÇÐ
  • Á¾¾çÇÐ

Á¦9Àå ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú¿¬±¸¼¾ÅÍ
  • È­»ó Áø´Ü¼¾ÅÍ
  • º´¿ø

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ÜÀϱ¤ÀÚ¹æÃâ ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Bruker Corporation
  • Digirad Corporation
  • General Electric Company
  • Koninklijke Philips NV
  • Mediso Ltd.
  • MiE GmbH
  • MILabs BV by Rigaku Corporation
  • Novartis AG
  • Siemens Healthineers AG
  • Spectrum Dynamics Medical Inc. by Biosensors International Group
  • The Bracco Group
BJH 24.12.24

The Single Photon Emission Computed Tomography Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.19 billion in 2024, and is projected to grow at a CAGR of 4.04%, to USD 2.77 billion by 2030.

Single Photon Emission Computed Tomography (SPECT) is a nuclear imaging technique that uses gamma rays to provide detailed three-dimensional images of functional processes in the body, typically utilized in cardiology, neurology, and oncology for diagnostics and treatment planning. The necessity of SPECT arises from its ability to deliver precise and early detection of diseases by highlighting metabolic changes, thus enabling more effective intervention. As healthcare demands increase with aging populations and the prevalence of chronic diseases, SPECT's ability to provide critical insights into conditions like coronary artery disease or tumor detection becomes invaluable. Its applications extend to drug development, enabling researchers to study human physiology and biochemistry with accuracy. The market sees significant growth influenced by technological advancements, such as improved imaging modalities and hybrid imaging techniques like SPECT/CT, enhancing diagnostic potency and expanding clinical applications. Opportunities lie in integrating machine learning and AI for improved image recognition and interpretation, which could reduce diagnostic errors and enhance technique efficiency. However, market growth faces challenges such as high equipment costs, limited reimbursement policies, and specialized skill requirements for operation and analysis. Furthermore, regulatory hurdles and slow adoption rates in emerging economies can pose significant constraints. To overcome these, increased investment in R&D for cost-effective, compact systems and collaborative efforts with tech companies for AI innovations could be pivotal. As a market analyst, focusing on partnerships with medical facilities for tailor-made solutions and expanding into untapped markets could drive growth. Additionally, developing portable SPECT devices may address cost concerns and accessibility, representing a promising research area in this evolving field. The nature of the market is competitive and innovation-driven, with a high potential for development through strategic investments in technology and broadened healthcare applications.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.19 billion
Forecast Year [2030] USD 2.77 billion
CAGR (%) 4.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Single Photon Emission Computed Tomography Market

The Single Photon Emission Computed Tomography Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cases of severla type of cancers and need for the advanced imaging technology
    • Growing demand for SPECT analysis in radiopharmaceuticals
  • Market Restraints
    • Shorter half-life of radioisotopes
  • Market Opportunities
    • Advancment in the single-photon emission computed tomography
  • Market Challenges
    • Prone to artifacts and attenuation

Porter's Five Forces: A Strategic Tool for Navigating the Single Photon Emission Computed Tomography Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Single Photon Emission Computed Tomography Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Single Photon Emission Computed Tomography Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Single Photon Emission Computed Tomography Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Single Photon Emission Computed Tomography Market

A detailed market share analysis in the Single Photon Emission Computed Tomography Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Single Photon Emission Computed Tomography Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Single Photon Emission Computed Tomography Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Single Photon Emission Computed Tomography Market

A strategic analysis of the Single Photon Emission Computed Tomography Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Single Photon Emission Computed Tomography Market, highlighting leading vendors and their innovative profiles. These include Bruker Corporation, Digirad Corporation, General Electric Company, Koninklijke Philips N.V., Mediso Ltd., MiE GmbH, MILabs BV by Rigaku Corporation, Novartis AG, Siemens Healthineers AG, Spectrum Dynamics Medical Inc. by Biosensors International Group, and The Bracco Group.

Market Segmentation & Coverage

This research report categorizes the Single Photon Emission Computed Tomography Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Hybrid SPECT Systems and Standalone SPECT Systems.
  • Based on Type of Radioisotopes, market is studied across Ga-67, I-123, Ra-223, and Tc-99m.
  • Based on Application, market is studied across Cardiology, Neurology, and Oncology.
  • Based on End User, market is studied across Academic & Research Centers, Diagnostic Imaging Centers, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cases of severla type of cancers and need for the advanced imaging technology
      • 5.1.1.2. Growing demand for SPECT analysis in radiopharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. Shorter half-life of radioisotopes
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancment in the single-photon emission computed tomography
    • 5.1.4. Challenges
      • 5.1.4.1. Prone to artifacts and attenuation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Single Photon Emission Computed Tomography Market, by Type

  • 6.1. Introduction
  • 6.2. Hybrid SPECT Systems
  • 6.3. Standalone SPECT Systems

7. Single Photon Emission Computed Tomography Market, by Type of Radioisotopes

  • 7.1. Introduction
  • 7.2. Ga-67
  • 7.3. I-123
  • 7.4. Ra-223
  • 7.5. Tc-99m

8. Single Photon Emission Computed Tomography Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Neurology
  • 8.4. Oncology

9. Single Photon Emission Computed Tomography Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Centers
  • 9.3. Diagnostic Imaging Centers
  • 9.4. Hospitals

10. Americas Single Photon Emission Computed Tomography Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Single Photon Emission Computed Tomography Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Single Photon Emission Computed Tomography Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bruker Corporation
  • 2. Digirad Corporation
  • 3. General Electric Company
  • 4. Koninklijke Philips N.V.
  • 5. Mediso Ltd.
  • 6. MiE GmbH
  • 7. MILabs BV by Rigaku Corporation
  • 8. Novartis AG
  • 9. Siemens Healthineers AG
  • 10. Spectrum Dynamics Medical Inc. by Biosensors International Group
  • 11. The Bracco Group
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦